Mallinckrodt plc (MNK) : Thursdays money flow data in Mallinckrodt plc (MNK) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $2.08 million, whereas, $1.6 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 1.3, in favor of the bulls. The total money flow into the stock was $0.48 million clearly indicating that the smart money has been buying into the stock on weakness.
In comparison, the money flow in block deals was $1.62 million. The total value of block trades done on upticks was $1.62 million. Mallinckrodt plc (MNK) fell $0.1 and traded at $62.06, down -0.16% for the day, over previous days close. On a weekly basis, the shares are -0.37% over the previous weeks close.
The stock has recorded a 20-day Moving Average of 5.12% and the 50-Day Moving Average is 3.14%. Shares have dropped -49.60% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $127.00 and the one year low was seen on Mar 16, 2016. The 50-Day Moving Average price is $60.67 and the 200 Day Moving Average price is recorded at $62.81.
Mallinckrodt plc (NYSE:MNK): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $62.77 and $61.94 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $63.00. The buying momentum continued till the end and the stock did not give up its gains. It closed at $62.45, notching a gain of 0.47% for the day. The total traded volume was 741,009 . The stock had closed at $62.16 on the previous day.
In an insider trading activity, Harbaugh Matthew K, CFO of Mallinckrodt Plc, executed a transaction worth $29,685 on May 10, 2016. A total of 500 shares were purchased at an average price of $59.37. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Mallinckrodt public limited company (Mallinckrodt) is a global specialty pharmaceuticals company. The Company develops, manufactures, markets and distributes both branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API) and diagnostic imaging agents. The Company uses its API products in the manufacture of its generic pharmaceuticals and also sells them to other pharmaceutical companies. The Company operates through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Companys Specialty Pharmaceuticals segment develops, manufactures and sells, through its Brands business, drugs, including EXALGO (hydromorphone HCl) Extended-Release Tablets and GABLOFEN. The Companys Global Medical Imaging segment develops, manufactures and markets contrast media and delivery systems (CMDS). The Company offers INOMAX Total Care (inhaled nitric oxide), a neonatal critical care product.